相关临床试验
31
8 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1992
进行中（未招募）
2
6.5%
已完成
11
35.5%
尚未招募
6
19.4%
招募中
2
6.5%
暂停
1
3.2%
终止
1
3.2%
Unknown
8
25.8%
暂无批准数据
- Researchers from NUS Medicine have developed a dual RNA-based therapy that effectively targets KRAS mutations, found in over 90% of pancreatic cancers and long considered "undruggable." - The combination treatment uses antisense oligonucleotides to silence mutant KRAS genes and immunomodulatory RNA to activate immune responses, delivered via red blood cell-derived extracellular vesicles. - Preclinical studies showed the therapy converted "cold" tumors into "hot" ones recognizable by the immune system, markedly suppressing tumor growth and extending survival without observable toxicity. - The platform shows particular promise for pancreatic ductal adenocarcinoma with peritoneal metastasis, addressing a major unmet medical need in one of cancer's deadliest forms.
- Researchers from NTU and MIT developed COMET, an AI model that predicts optimal lipid nanoparticle formulations for RNA medicine delivery, published in Nature Nanotechnology. - The transformer-based neural network can identify the best nanoparticle designs among millions of possibilities without extensive laboratory testing, reducing development timelines from months to weeks. - COMET-designed lipid nanoparticles outperformed clinically approved benchmarks in both laboratory and animal studies, demonstrating superior delivery performance. - The technology extends beyond pandemic preparedness to enable RNA therapies targeting specific organs and cell types for treating cancers and metabolic disorders.
